Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is conditionally approved by the Hong Kong Department of Health for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID™ (nirmatrelvir tab; ritonavir tab)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Did you find an answer to your question? Yes No
Contact Us
Report Adverse Event

Please visit www.pfizersafetyreporting.com to report or contact us at (+852) 2811 9711